OncoSynergy: Detoxing its target
OncoSynergy designs OS2966 to safely inhibit integrin beta(1) for brain cancer
While integrin beta(1) is involved in tumor growth and metastasis, cancer researchers have long assumed that targeting the protein would be prohibitively toxic because of its essential role in normal cellular signaling processes. OncoSynergy Inc. is developing a first-in-class antibody that is designed to safely block a subset of integrin beta(1) interactions to treat solid tumors.
The company also thinks its product's ability to tamp down multiple cancer-related processes will have an advantage over competing compounds that only block one or two mechanisms...